ResearcherUniversity of ZurichNo recent work listed

Christian Hirt

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-8237-2451; OpenAlex author ID A5003446778. Sources: OpenAlex.

Their work

Papers: 3
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 9

Papers, trials and grants by year

2021: 1 paper · 2022: 2 papers

Papers 3

SF3B1 facilitates HIF1-signaling and promotes malignancy in pancreatic cancer. Co-author DOI 10.1016/j.celrep.2022.111266 ↗
Drug screening and genome editing in human pancreatic cancer organoids identifies drug-gene interactions and candidates for off-label treatment. Co-author DOI 10.1016/j.xgen.2022.100095 ↗
Identification of HIF-dependent alternative splicing in gastrointestinal cancers and characterization of a long, coding isoform of SLC35A3 Co-author DOI 10.1016/j.ygeno.2020.12.039 ↗

Closest collaborators

The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Gerald Schwank · 3 shared papers, 2021–2022 · strength 0.36
Gunnar Rätsch · 2 shared papers, 2021–2022 · strength 0.25
- Paper Identification of HIF-dependent alternative splicing in gastrointestinal cancers and characterization of a long, coding… DOI 10.1016/j.ygeno.2020.12.039 ↗
- Paper SF3B1 facilitates HIF1-signaling and promotes malignancy in pancreatic cancer. DOI 10.1016/j.celrep.2022.111266 ↗
Chantal Pauli · 2 shared papers, 2022 · strength 0.22
- Paper Drug screening and genome editing in human pancreatic cancer organoids identifies drug-gene interactions and candidates… DOI 10.1016/j.xgen.2022.100095 ↗
- Paper SF3B1 facilitates HIF1-signaling and promotes malignancy in pancreatic cancer. DOI 10.1016/j.celrep.2022.111266 ↗
Daniela M. Lenggenhager · 2 shared papers, 2022 · strength 0.22
- Paper Drug screening and genome editing in human pancreatic cancer organoids identifies drug-gene interactions and candidates… DOI 10.1016/j.xgen.2022.100095 ↗
- Paper SF3B1 facilitates HIF1-signaling and promotes malignancy in pancreatic cancer. DOI 10.1016/j.celrep.2022.111266 ↗
Patrik Simmler · 2 shared papers, 2022 · strength 0.22
- Paper Drug screening and genome editing in human pancreatic cancer organoids identifies drug-gene interactions and candidates… DOI 10.1016/j.xgen.2022.100095 ↗
- Paper SF3B1 facilitates HIF1-signaling and promotes malignancy in pancreatic cancer. DOI 10.1016/j.celrep.2022.111266 ↗
Philipp Markolin · 1 shared paper, 2021 · strength 0.14
- Paper Identification of HIF-dependent alternative splicing in gastrointestinal cancers and characterization of a long, coding… DOI 10.1016/j.ygeno.2020.12.039 ↗
Hagen Klett · 1 shared paper, 2022 · strength 0.11
- Paper Drug screening and genome editing in human pancreatic cancer organoids identifies drug-gene interactions and candidates… DOI 10.1016/j.xgen.2022.100095 ↗
Ilaria Guccini · 1 shared paper, 2022 · strength 0.11
- Paper SF3B1 facilitates HIF1-signaling and promotes malignancy in pancreatic cancer. DOI 10.1016/j.celrep.2022.111266 ↗
Markus Stoffel · 1 shared paper, 2022 · strength 0.11
- Paper SF3B1 facilitates HIF1-signaling and promotes malignancy in pancreatic cancer. DOI 10.1016/j.celrep.2022.111266 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.